Marta Consuegra-Fernández

Marta Consuegra-Fernández

Auto-generated profile, based on publicly available information

Marta Consuegra-Fernández

Universitat de Barcelona

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MOMarc Orta-Mascaró
Marc Orta-Mascaró
MCMarta Consuegra-Fernández
Marta Consuegra-Fernández
ECEsther Carreras
Esther Carreras
RRRomain Roncagalli
Romain Roncagalli
ACAmado Carreras-Sureda
Amado Carreras-Sureda
LFLozano Francisco
Lozano Francisco
The CD6 glycoprotein is a lymphocyte surface receptor putatively involved in T cell development and activation. CD6 facilitates adhesion between T cells and antigen-presenting cells through its interaction with CD166/ALCAM (activated leukocyte cell adhesion molecule), and physically associates with the T cell receptor (TCR) at the center of the immunological synapse. However, its precise role during thymocyte development and peripheral T cell immune responses remains to be defined. Here, we analyze the in vivo consequences of CD6 deficiency. CD6−/− thymi showed a reduction in both CD4+ and CD8+ single-positive subsets, and double-positive thymocytes exhibited increased Ca2+ mobilization to TCR cross-linking in vitro. Bone marrow chimera experiments revealed a T cell–autonomous selective disadvantage of CD6−/− T cells during development. The analysis of TCR-transgenic mice (OT-I and Marilyn) confirmed that abnormal T cell selection events occur in the absence of CD6. CD6−/− mice displayed increased frequencies of antigen-experienced peripheral T cells generated under certain levels of TCR signal strength or co-stimulation, such as effector/memory (CD4+TEM and CD8+TCM) and regulatory (T reg) T cells. The suppressive activity of CD6−/− T reg cells was diminished, and CD6−/− mice presented an exacerbated autoimmune response to collagen. Collectively, these data indicate that CD6 modulates the threshold for thymocyte selection and the generation and/or function of several peripheral T cell subpopulations, including T reg cells.

16 June 2014 in FEBS Letters
Verified
Journal Article
Closed access
CECristina Escoda-Ferran
Cristina Escoda-Ferran
ECEsther Carrasco
Esther Carrasco
MCMiguel Caballero-Baños
Miguel Caballero-Baños
CMCristina Miró-Julià
Cristina Miró-Julià
MMMario Martínez-Florensa
Mario Martínez-Florensa
LFLozano Francisco
Lozano Francisco

12 June 2017 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MVMarcos Vasquez
Marcos Vasquez
ISInês Simões
Inês Simões
MCMarta Consuegra‐Fernández
Marta Consuegra‐Fernández
Fernando ArandaFernando Aranda
Fernando Aranda
LFLozano Francisco
Lozano Francisco
Pedro BerraondoPedro Berraondo
Pedro Berraondo

1 April 2018 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SRSoledad Retamozo
Soledad Retamozo
AFAlejandra Flores-Chavez
Alejandra Flores-Chavez
MCMarta Consuegra-Fernández
Marta Consuegra-Fernández
LFLozano Francisco
Lozano Francisco
MRManuel Ramos-Casals
Manuel Ramos-Casals
PBPilar Brito-Zerón
Pilar Brito-Zerón

30 May 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
MCMarta Consuegra-Fernández
Marta Consuegra-Fernández
MMMario Martínez-Florensa
Mario Martínez-Florensa
Fernando ArandaFernando Aranda
Fernando Aranda
JSJosé de Salort
José de Salort
NANoelia Armiger-Borràs
Noelia Armiger-Borràs
LFLozano Francisco
Lozano Francisco
The CD6 lymphocyte receptor has been involved in the pathophysiology of different autoimmune disorders, and is now considered a feasible target for their treatment. In vitro data show the relevance of CD6 in the stabilization of adhesive contacts between T-cell and Antigen Presenting Cells, and the modulation of T-cell receptor (TCR) signals. However, the in vivo consequences of such a function are yet undisclosed due to the lack of suitable genetically modified animal models. Here, the in vitro and in vivo challenge of CD6-deficient (CD6-/-) cells with allogeneic cells was used as an approach to explore the role of CD6 in immune responses under relative physiological stimulatory conditions. Mixed Lymphocyte Reaction (MLR) assays showed lower proliferative responses of splenocytes from CD6-/- mice together with higher induction of regulatory T cells (Treg, CD4+CD25+FoxP3+) with low suppressive activity on T and B cell proliferation. In line with these results, CD6-/- mice undergoing a lupus-like disorder induced by chronic graft versus host disease (cGvHD) showed higher serum titres of anti-double stranded DNA and nucleosome autoantibodies. This occurred together with reduced splenomegaly, which was associated with lower in vivo bromodesoxyuridine incorporation of spleen cells and with increased percentages of spleen follicular B cells (B2, CD21+CD23hi) and Treg cells. Interestingly, functional analysis of in vivo-generated CD6-/- Treg cells exhibited defective suppressive activity. In conclusion, the data from MLR and cGvHD-induced lupus-like models in CD6-/- mice illustrate the relevance of CD6 in T (and B) cell proliferative responses and, even more importantly, Treg induction and suppressive function in the in vivo maintenance of peripheral tolerance.

1 January 2015 in Critical Reviews in Immunology
Verified
Journal Article
Closed access
PDF file
MCMarta Consuegra-Fernandez
Marta Consuegra-Fernandez
Fernando ArandaFernando Aranda
Fernando Aranda
ISInes Simoes
Ines Simoes
MOMarc Orta
Marc Orta
ASAdelaida Sarukhan
Adelaida Sarukhan
LFLozano Francisco
Lozano Francisco
CD5 was one of the first surface receptors described for mouse and human T lymphocytes. Since then, it has been found to be highly expressed by regulatory T cells and a subpopulation of regulatory B cells, to be physically associated with the T- and B-cell antigen receptors, to negatively modulate TCR- and BCR-mediated signals, and to bind certain pathogen-associated molecular patterns. These findings position CD5 as an attractive target for developing immunotherapies aimed at either boosting or dampening ongoing immune responses. Here the available data on the function of CD5 and its involvement in the regulation of immune responses in health and disease are reviewed, as well as the evidence for and future challenges in developing therapeutic strategies aimed at targeting CD5 for autoimmune diseases, cancer, and infections.